Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly

Decreased number of inpatients with community-acquired pneumonia during the COVID-19 pandemic: A large multicenter study in Japan

(2022) Yan Yan et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

(2022) Miwako Kobayashi et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Pneumococcal meningitis in adults in 2014–2018 after introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan

(2022) Bin Chang et al.   Scientific Reports

Efficacy and Effectiveness of a 23-Valent Polysaccharide Vaccine Against Invasive and Non-Invasive Pneumococcal Disease and Related Outcomes: A Review of Available Evidence

(2021) Michael S. Niederman et al.   Expert Review of Vaccines

Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors

(2021) Kenneth J. Smith et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Hospitalization of mild cases of community-acquired pneumonia decreased more than severe cases during the COVID-19 pandemic

(2021) Hiroyuki Nagano et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK

(2021) Andrew Vyse et al.   Expert Review of Vaccines

A review of health-related quality of life associated with pneumococcal disease: pooled estimates by age and type of disease

(2021) Zhaoli Tang et al.   JOURNAL OF PUBLIC HEALTH

The impact of acute pneumococcal disease on health state utility values: a systematic review

(2021) Ryan O’Reilly et al.   QUALITY OF LIFE RESEARCH

One-Year Quality of Life Post-Pneumonia Diagnosis in Japanese Adults

(2020) Henry A Glick et al.   CLINICAL INFECTIOUS DISEASES

A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population

(2020) Jacob Dag Berild et al.   Pathogens

Epidemiological and clinical features of invasive pneumococcal disease caused by serotype 12F in adults, Japan

(2019) Reiko Shimbashi et al.   PLoS One

Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE)

(2019) Eiichiro Sando et al.   VACCINE

Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium

(2018) Lander Willem et al.   Human Vaccines & Immunotherapeutics

Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study

(2017) Motoi Suzuki et al.   LANCET INFECTIOUS DISEASES

Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D

(2015) Takeru Shiroiwa et al.   QUALITY OF LIFE RESEARCH

The Burden and Etiology of Community-Onset Pneumonia in the Aging Japanese Population: A Multicenter Prospective Study

(2015) Konosuke Morimoto et al.   PLoS One